Silence Therapeutics (SLN)
(Delayed Data from NSDQ)
$22.19 USD
+0.29 (1.32%)
Updated May 7, 2024 04:00 PM ET
After-Market: $22.29 +0.10 (0.45%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Income Statements
Fiscal Year end for Silence Therapeutics PLC Sponsored ADR falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 32 | 22 | 17 | 7 | NA |
Cost Of Goods | 13 | 13 | 10 | 5 | NA |
Gross Profit | 19 | 8 | 7 | 2 | NA |
Selling & Adminstrative & Depr. & Amort Expenses | 80 | 68 | 70 | 48 | 0 |
Income After Depreciation & Amortization | -62 | -60 | -63 | -46 | 0 |
Non-Operating Income | 2 | 2 | 0 | 0 | NA |
Interest Expense | 3 | 0 | 0 | 0 | NA |
Pretax Income | -63 | -59 | -63 | -46 | NA |
Income Taxes | -9 | -9 | -9 | -4 | NA |
Minority Interest | 0 | 0 | 0 | 0 | NA |
Investment Gains/Losses | 0 | 0 | 0 | 0 | NA |
Other Income/Charges | 0 | 0 | 0 | 0 | NA |
Income From Cont. Operations | -54 | -50 | -54 | -42 | NA |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | NA |
Net Income (GAAP) | -54 | -50 | -54 | -42 | NA |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -61 | -60 | -62 | -45 | 0 |
Depreciation & Amortization (Cash Flow) | 1 | 1 | 1 | 1 | NA |
Income After Depreciation & Amortization | -62 | -60 | -63 | -46 | 0 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 37.08 | 32.21 | 29.65 | 81.78 | NA |
Diluted EPS Before Non-Recurring Items | -1.45 | -1.56 | -1.83 | -0.40 | NA |
Diluted Net EPS (GAAP) | -1.45 | -1.55 | -1.83 | -1.53 | NA |
Fiscal Year end for Silence Therapeutics PLC Sponsored ADR falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 2.81 | 3.54 | 11.40 | 13.82 |
Cost Of Goods | NA | 1.75 | 2.03 | 3.54 | 5.51 |
Gross Profit | NA | 1.06 | 1.51 | 7.85 | 8.31 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 17.59 | 17.58 | 22.20 | 23.07 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -16.53 | -16.07 | -14.35 | -14.76 |
Non-Operating Income | NA | -1.63 | 2.59 | 0.43 | 0.41 |
Interest Expense | NA | 0.50 | 0.01 | 1.12 | 1.04 |
Pretax Income | NA | -18.65 | -13.50 | -15.04 | -15.40 |
Income Taxes | NA | -0.69 | -3.05 | -2.01 | -3.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -17.96 | -10.44 | -13.02 | -12.40 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -17.96 | -10.44 | -13.02 | -12.40 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 38.43 | 37.16 | 36.12 | 35.80 |
Diluted EPS Before Non-Recurring Items | NA | -0.47 | -0.28 | -0.36 | -0.35 |
Diluted Net EPS (GAAP) | NA | -0.46 | -0.28 | -0.36 | -0.35 |